Citations

Clear

4510 citation(s) found for "Scott, C".

Factors Associated With More Medication Trials Before Surgical Evaluation and Postsurgical Outcomes in Pediatric Drug-Resistant Epilepsy
Samanta, Debopam , Newell, Grace, Caraway, Avery Robert, Brock, Emily, Albert, Gregory W. , Novotny, Edward J. , Cabacar, Dewi Frances Depositario, Gaillard, William D. , Tatachar, Priyamvada , Bolton, Jeffrey , Romanowski, Erin Fedak , Alexander, Allyson , Auguste, Kurtis I. , Bernardo, Danilo , Ostendorf, Adam P. , Karia, Samir , Karakas, Cemal , Pichon, P, Olaya, Joffre , Shrey, Daniel W. , Reddy, Shilpa B. , Ganesh, Abhinaya, Hauptman, Jason S. , Singh, Rani K. , Ciliberto, Michael A. , Marashly, Ahmad , Nangia, Srishti, Arredondo, Kristen H. , Miller, D. , Sattar, Shifteh , Montenegro, Maria Augusta , Agarwal, Nitin , Galán, Fernando , Wagner, Janelle L. , Knox, Andrew , Perry, Μ. Scott , Caraway, Avery R. , Caraway, Avery Robert , Novotny, Edward J , Depositario Cabacar, Dewi Frances , Oluigbo, Chima O , Gaillard, William D , Tatachar, Priyamvada , Bolton, Jeffrey Brian , Wong-Kisiel, Lily C. , Fedak Romanowski, Erin , McNamara, Nancy A , Eschbach, Krista , Alexander, Allyson L , Auguste, Kurtis I , Gonzalez-Giraldo, Ernesto , Bernardo, Danilo , Ostendorf, Adam P , Coryell, Jason , Karia, Samir , Karakas, Cemal , Javarayee, Pradeep K , Pichon, Pilar D , Shrey, Daniel W , Reddy, Shilpa B , Ganesh, Abhinaya , Hauptman, Jason , Singh, Rani K , Ciliberto, Michael A , Marashly, Ahmad , Grinspan, Zachary , Arredondo, Kristen H , Miller, Derryl J , Montenegro, Maria , Agarwal, Nitin , Galan, Fernando N , Abel, Taylor J , Knox, Andrew T , Perry, Michael Scott , Newell, Grace, Brock, Emily, Oluigbo, Chima , Wong‐Kisiel, Lily C. , McNamara, Nancy , Eschbach, Krista , Gonzalez‐Giraldo, Ernesto , Coryell, Jason , Javarayee, Pradeep , Grinspan, Zachary M. , Abel, Taylor J.

Mayo Clinic

Neurology | October 7, 2025 | Volume: 105 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000214198 | PMID 41056528 Get It

Impact of prior authorization for oncology medications on practices with majority rural patient populations.
McGovern, Emily , Troy, Jeanie, Hughes, Heidi, Nelson, Lisa , Yuan, R., Nelson, Kristina R., Perschke, Grant, Ticku, Jonathan, Kamboj, Jasmine , Pritchett, Joshua C. , Schroeder, Zachary, Troy, Jeanie, Hughes, Heidi, Nelson, Lisa, Nelson, Kristina R., Kelly, Benjamin, Soefje, Scott A. , Swenson, Wade T.

Mayo Clinic

JCO Oncology Practice | October 7, 2025 | Volume: 21 | Issue: 10_suppl | Pages: 55-55

10.1200/op.2025.21.10_suppl.55 Get It

55 Background: Prior authorization (PA) processes are known to create administrative burdens and delays in care, but little is known about how these challenges impact rural oncology patients and practice settings. Methods: To understand the broad impact of prior authorization on rural oncology patients and practices, we conducted this study across three community oncology practices serving majority rural patient populations with distinct geography, healthcare infrastructure, and models of care. Sites included one critical access hospital system located in a highly-rural community (Lakewood Health System; Staples, Minnesota), a community-based hub-and-spoke hospital system-based practice located in a mid-sized community (Mayo Clinic Health System – Northfield; Northfield, Minnesota), and a standalone referral level III trauma center serving a highly rural patient base (Self Regional Healthcare; Greenwood, South Carolina). This retrospective cohort study examined all intravenous and subcutaneous cancer-directed therapy plans (no oral therapy) that required PA submission at these locations over a three-month period from October 1, 2024 to December 31, 2024. Results: 129 PA submissions were required during the study period. 82 were due to cancer-directed therapy agents (of which 14 were immunotherapy agents), and 47 were due to adjunctive therapies (of which 22, 16, and 9 were due to granulocyte stimulation, bone preservation, and anti-emesis agents, respectively). All 129 PA submissions ultimately resulted in approval of the desired medication or formulary-approved biosimilar. Delays from PA submission to approval ranged from 0 to 18 days. A total of 209 patient-days were delayed due to PA during the study period, which did not ultimately result in change of care or denial of care in any instance. Conclusions: At all sites included in this study, all PA submissions were eventually authorized. The PA process was found to introduce inconsistent and potentially avoidable delays for hundreds of patients and their care teams. These findings highlight the inefficiency of current PA processes among rural cancer populations and the practices that care for them, underscoring the need for ongoing efforts directed at state and federal PA reform.
High-Intensity Atorvastatin and 24-Hour Blood Pressure in Obstructive Sleep Apnea: A Randomized, ­Double-Blind, Placebo-Controlled Pilot Study
Bock, Joshua M. , Vungarala, Soumya , Sompalli, Sreeja , Covassin, Naima , Bukartyk, Jan , Louis, Erik K. St. , Wright, R. Scott , Singh, Prachi , Somers, Virend K. , Karim, Shahid , St Louis, E K , Singh, Prachi , Bock, Joshua , Karim, Shahid, Somers, Virend K.

Mayo Clinic

American Journal of Hypertension | October 7, 2025 | Volume: 39 | Issue: 3 | Pages: 390-399

10.1093/ajh/hpaf202 | PMID 41072928 Get It

Abstract Background Obstructive sleep apnea (OSA) is a risk factor for hypertension and some evidence suggests this risk may not be mitigated with positive airway pressure. Low-intensity statin therapy can modestly reduce blood pressure (BP). In this exploratory analysis, we examined if six months of high-intensity statin therapy could lower resting or ambulatory BP in patients with OSA. Methods 39 patients with OSA (13F, age = 49 ± 9yrs, body mass index = 32.9 ± 4.2kg/m2, apnea-hypopnea index = 22.2 ± 12.4 events/hour) were randomized to high-intensity atorvastatin or placebo. BP was assessed using seated, “office” measurements and in 20-minute intervals over 24 consecutive hours at three timepoints (baseline, three- and six-months post-randomization). Participants maintained a diary denoting sleep and wake times for analysis. Changes (Δ) in BP from baseline were assessed and adjusted for adherence to participants’ intervention (atorvastatin or placebo) as well as to their treatment for OSA (yes or no). Results There were no between-group differences in baseline BP variables (P = .09-.96). At three months, the changes in resting (P = .74-.87), 24 hour mean (P = .54-.96), daytime (P = .70-.96), nor nighttime (P = .74-.96) BP did not differ between groups. Similarly, the changes in resting (P = .23-.92), 24 hour mean (P = .51-.82), daytime (P = .17-.78), and nighttime (P = .51-1.00) BP did not differ between groups following six months of their respective intervention. Conclusions Our data suggest that high-intensity atorvastatin does not lower resting or ambulatory BP in patients with OSA relative to a placebo. Thus, it does not appear that atorvastatin is a viable adjunct intervention for BP reduction in patients with OSA. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03308578.
Outcomes of Early-Life Focal Cortical Dysplasia–Related Epilepsy
Cohen, Nathan T. , Depositario‐Cabacar, Dewi, Ostendorf, Adam P. , Wong‐Kisiel, Lily C. , Romanowski, Erin Fedak , McNamara, Nancy , Tatachar, Priyamvada , Eschbach, Krista , Alexander, Allyson , Pichon, P, Ciliberto, Michael A. , Bernardo, Danilo , Auguste, Kurtis I. , Arredondo, Kristen H. , Reddy, Shilpa B. , Ganesh, Abhinaya, Marashly, Ahmad , Singh, Rani K. , Bolton, Jeffrey , Karia, Samir , Karakas, Cemal , Lin, Jenny , Knox, Andrew , Samanta, Debopam , Armstrong, Dallas , Pavuluri, Spriha , Hyslop, Ann , Galán, Fernando , Miller, D. , Hauptman, Jason S. , Caraway, Avery Robert, Perry, Μ. Scott , Caraway, Avery R. , Oluigbo, Chima O , Ostendorf, Adam P , Wong-Kisiel, Lily C. , Fedak Romanowski, Erin , McNamara, Nancy A , Tatachar, Priyamvada , Eschbach, Krista , Alexander, Allyson L , Pichon, Pilar D , Ciliberto, Michael A , Gonzalez-Giraldo, Ernesto , Bernardo, Danilo , Auguste, Kurtis I , Coryell, Jason , Arredondo, Kristen H , Novotny, Edward J , Reddy, Shilpa B , Ganesh, Abhinaya , Marashly, Ahmad , Javarayee, Pradeep K , Singh, Rani K , Bolton, Jeffrey Brian , Grinspan, Zachary , Karia, Samir , Karakas, Cemal , Lin, Jenny , Knox, Andrew T , Wolf, Steven , Abel, Taylor J , Samanta, Debopam , Armstrong, Dallas Michael , Hyslop, Ann , Galan, Fernando N , Miller, Derryl J , Hauptman, Jason , Caraway, Avery Robert , Perry, Michael Scott , Gaillard, William D , Oluigbo, Chima , Gonzalez‐Giraldo, Ernesto , Coryell, Jason , Novotny, Edward J. , Javarayee, Pradeep , Grinspan, Zachary M. , Wolf, Steven M. , Abel, Taylor J. , Gaillard, William D.

Mayo Clinic

Neurology Clinical Practice | October 6, 2025 | Volume: 15 | Issue: 6 | Pages: No page available

10.1212/cpj.0000000000200539 | PMID 41070137 Get It

Ceramide test in patients with erectile dysfunction to assess cardiovascular risk
Guillén-Lozoya, A.H. , Dumbrava, Mihai, Bonakdarhashemi, Milad, Kemble, Jayson , Ziegelmann, Matthew , Vasile, Vlad C. , Kopecky, Stephen L. , Köhler, Tobias , Lozoya, Andres Guillen , Helo, Sevann , Collins, Scott, Vasile, Vlad , Kopecky, Stephen, Collins, Scott

Mayo Clinic

The Journal of Sexual Medicine | October 5, 2025 | Volume: 22 | Issue: 10 | Pages: 1750-1756

10.1093/jsxmed/qdaf182 | PMID 41046349 Get It

Abstract Background Erectile dysfunction (ED) is a known precursor and sequela of cardiovascular disease (CVD), with ED severity predicting CVD severity. Aim This study aimed to evaluate the utility of ceramide levels in patients with ED. Methods We initiated ceramide testing in all patients with ED. We retrospectively analyzed ceramide levels from electronic records and stratified by severity of symptoms using the erectile function domain of the International Index of Erectile Function (IIEF). Outcomes The study aimed to determine whether abnormal ceramide levels were associated with ED severity and increased cardiovascular risk. Results Three hundred and fifty-four patients were reviewed, of whom 253 (71.5%) had moderate or higher ED. A statistically significant difference in abnormal ceramide values was found in patients with moderate to severe symptoms, and the odds of getting an abnormal ceramide test were increased based on the IIEF scoring alone (odds ratio [OR] 2.3 [1.04-5.12]; P-value = .034). Clinical Implications Serum ceramide testing could be beneficial in identifying cardiovascular risk in men with ED, potentially prompting cardiac referrals and lifestyle modifications. Strengths and Limitations The strengths of this study include a large sample size and the use of a well-established scale, while the limitations include the retrospective nature of the study and the need for further research to validate the findings. Conclusion Patients undergoing management for ED may benefit from serum ceramide testing and subsequent cardiac referral.
Cephalic Vein Interposition Graft for Salvage of Compromised DIEP Flap in Breast Reconstruction
Kumar, Nishant , Odorico, Scott K. , Vijayasekaran, Aparna , Odorico, Scott K , Vijayasekaran, Aparna , Bustos, Samyd S.

Mayo Clinic

Microsurgery | October 3, 2025 | Volume: 45 | Issue: 7 | Pages: No page available

10.1002/micr.70124 | PMID 41042018 Get It

ABSTRACT The deep inferior epigastric perforator (DIEP) flap remains the preferred flap option for autologous breast reconstruction following mastectomy. This case report presents the novel use of the cephalic vein (CV) as an interposition graft to alleviate venous congestion in a patient undergoing DIEP flap reconstruction. A 42‐year‐old woman experienced venous congestion following her initial autologous reconstruction, attributed to thrombus formation from kinking of the vascular pedicle. Despite initial attempts to resolve the congestion, the condition persisted. Since the flap was based on a single perforator, we decided to attempt a CV turndown. The CV was noted to be attenuated and not feasible for use in turndown; therefore, venous salvage was completed by using the CV as an interposition graft to bypass the affected flap vena comitans. The procedure successfully restored venous flow, allowing for flap salvage and subsequent healing. This case underscores the potential of CV as an interposition graft in autologous breast reconstruction, particularly when traditional CV turndown is not possible due to vessel attenuation.
EACTS Expert Consensus Document on protected cardiac surgery: pre-emptive use of temporary mechanical circulatory support in adult cardiac surgery patients at high risk for perioperative low cardiac output syndrome
Lorusso, Roberto , Salazar, Leonardo , Nersesian, Gaik , Wiedemann, Dominik , Goldstein, Daniel, Soltesz, Edward G. , Bermúdez, C. , Haft, Jonathan W., Patel, Bhavesh , Moreno, Pedro , Tonna, Joseph E. , Lamarche, Yoan , Rao, V., Meyns, Bart , Takeda, Koji , Whitman, Glenn, Potapov, Evgenij, Group, EACTS Scientific Document, Sartipy, Ulrik , Fux, Thomas , Turina, Marko , Morshuis, Michiel , Knosalla, Christoph , Milojevic, Milan , Zimpfer, Daniel , Wiedemann, Dominik , Takayama, Hiroo , Rao, Vivek , Meyns, Bart , Potapov, Evgenij , Tonna, Joseph E. , Lorusso, Roberto , Schmack, Bastian , Engelman, Daniel T. , Stein, Louis H. , Silvestry, Scott , Zimpfer, Daniel , Moreno, Pedro , MacLaren, Graeme , Takayama, Hiroo , Färber, Gloria , Boeken, Udo , Arora, Rakesh C. , Group, EACTS Scientific Document, Russo, Claudio , Meineri, Massimiliano , Paparella, Domenico

Mayo Clinic

European Journal of Cardio-Thoracic Surgery | October 2, 2025 | Volume: 68 | Issue: 3 | Pages: No page available

10.1093/ejcts/ezaf296 | PMID 41063414 Get It

Abstract Perioperative low cardiac output syndrome (LCOS) remains a significant complication in adult cardiac surgery, contributing to substantial morbidity, prolonged intensive care, and increased mortality. Its incidence is expected to rise further due to the evolving complexity of referred surgical patients, often characterised by advanced age, multiple comorbidities, challenging anatomy, and impaired haemodynamics. Despite advances in pharmacological and perioperative care, outcomes for high-risk patients have not shown significant improvement, prompting interest in temporary mechanical circulatory support (tMCS) as a proactive strategy. This Expert Consensus Document from the European Association for Cardio-Thoracic Surgery (EACTS) presents the first dedicated guidance on the pre-emptive use of tMCS in high-risk adult cardiac surgical patients. Developed by a multidisciplinary task force, it emphasises structured risk stratification, early initiation, and individualised device management informed by interdisciplinary Heart Team discussions. The document proposes clinical pathways for patient selection, defines criteria for tMCS initiation, and provides practical algorithms for various scenarios, including advanced heart failure, cardiogenic shock, and post-cardiotomy LCOS. It reviews the current evidence on available tMCS devices, such as intra-aortic balloon pumps, microaxial flow pumps, veno-arterial extracorporeal life support and hybrid strategies, and addresses perioperative care, intensive care unit protocols, ethical considerations, as well as informed consent and support withdrawal. Despite promising results, substantial knowledge gaps remain, including long-term outcome data, device selection criteria, and cost-effectiveness analyses. This consensus aims to support clinical decision-making, standardise practice, and stimulate research to improve outcomes in a growing population of high-risk surgical patients.
Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results
Wieduwilt, Matthew J. , Yin, Jun , Kour, Oudom, Teske, Rebecca, Stock, Wendy , Escherich, Carolin S. , Byrd, Kenneth, Doucette, Kimberley , Mangan, James K. , Hall, Scott, Jamieson, Katarzyna , Dinner, Shira, Bseiso, Ali W., Giordano, Giorgia , Saygin, Caner , Litzow, Mark R. , Stone, Richard M. , Escherich, Carolin , Yang, Jun J.J. , Mims, Alice S , Uy, Geoffrey , Litzow, Mark R. , Stone, Richard M , Stock, Wendy , Wieduwilt, Matthew J , Li, Zhenhua , Uy, Geoffrey L.

Mayo Clinic

Journal of Clinical Oncology | September 30, 2025 | Volume: 43 | Issue: 32 | Pages: 3526-3535

10.1200/jco-25-00307 | PMID 41026957 Get It

PURPOSE Older patients with ALL receiving conventional chemotherapy have poor survival due to toxic death and relapse. We hypothesized that a chemotherapy-free, targeted regimen using the anti-CD22 antibody-calicheamicin conjugate inotuzumab ozogamicin followed by the bispecific anti-CD19/CD3 T-cell engager blinatumomab would reduce toxic death and yield high rates of prolonged remission and survival. METHODS Eligible patients were age 60 years and older with untreated, Philadelphia chromosome (Ph)–negative, CD22-positive, B-cell ALL. Patients received up to two cycles of inotuzumab ozogamicin followed by four or five cycles of blinatumomab with intrathecal methotrexate CNS prophylaxis. The primary end point was 1-year event-free survival (EFS). RESULTS The 33 eligible patients had a median age of 71 years (range, 60-84) and a median CD22 expression of 92% (range, 21%-100%). Eight (24%) had previous chemotherapy or radiation for other cancers, six for multiple myeloma. The composite complete remission rate was 85% after two cycles of inotuzumab ozogamicin and 97% by the end of two cycles of blinatumomab. At a median follow-up of 30 months, the 1-year EFS and overall survival were 75% (95% CI, 61 to 92) and 85% (95% CI, 73 to 98), respectively. EFS was shorter with lower CD22 expression or detectable measurable residual disease at any time point. CONCLUSION Inotuzumab ozogamicin then blinatumomab without maintenance chemotherapy in older patients with untreated, Ph-negative, CD22-positive, B-cell ALL yields a high remission rate and excellent EFS. Given the lack of standard, safe, and effective therapies in this population, the regimen should be considered a standard treatment option.
Leptomeningeal Metastatic Disease: Patient Characteristics and Symptom Burden at a Large Tertiary Referral Center
Fahrner-Scott, Kelly , Bell, Brieze K. , O’Riordan, David L. , Boreta, Lauren , Rabow, Michael W.

Mayo Clinic

JCO Oncology Advances | September 30, 2025 | Volume: No volume available | Issue: 2 | Pages: No page available

10.1200/oa-25-00028 Get It

PURPOSE Leptomeningeal metastatic disease (LMD) is associated with poor prognosis and imposes severe symptomatic limitations on functional status and quality of life. In recent years, the range of diagnostic and therapeutic options available to patients with LMD has expanded, but the impact of these innovations on clinical characteristics and outcomes remains unclear. We conducted a retrospective study to define the LMD patient population, symptoms experienced, and the frequency of accessing specialty palliative care (PC) services, at a large tertiary referral center. METHODS We conducted a retrospective electronic medical record review on the basis of a convenience sample of 104 patients diagnosed and treated with LMD with dates of diagnosis between January 1, 2016, and October 1, 2022. Variables were generated on the basis of patient demographics, reported symptoms, and clinical course. Data were analyzed using Stata 16. RESULTS Of 104 patients in the analysis, the most common symptoms reported were headache and extremity weakness (52% of patients reported each). The mean number of weeks between LMD diagnosis and date of death was 41.4, with a median of 27.9 weeks, and a range of 1.4-143.4 weeks. Forty-five percent of patients had at least one documented visit with an inpatient or outpatient PC provider. CONCLUSION Patients with an LMD diagnosis face a high symptom burden. Our findings highlight that prognosis may be longer than what is typically quoted in the literature, but further study would be needed to understand this discrepancy. Fewer than half of the patients in our sample had a documented visit with a PC specialist, suggesting a missed opportunity in this population to connect with providers specialized in managing symptom burden and doing nuanced advance care planning.
Classifying hypopneas as obstructive or central can enhance transvenous phrenic nerve stimulation therapy patient selection and outcomes
Dupuy-McCauley, Kara , Javaheri, Shahrokh, Germany, Robin , McKane, Scott , Schwartz, Alan R. , Morgenthaler, Timothy I.

Mayo Clinic

Journal of Clinical Sleep Medicine | September 30, 2025 | Volume: 21 | Issue: 12 | Pages: 2113-2120

10.5664/jcsm.11904 | PMID 41025409 Get It